Philip Morris Faces Challenges Amid FDA Resistance to Nicotine Pouch Approval
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 16 2025
0mins
Should l Buy PM?
Philip Morris International Inc (PM) has seen its stock price decline as it hits a 20-day low amid broader market gains, with the Nasdaq-100 up 0.75% and the S&P 500 up 0.55%.
The recent resistance to the FDA's fast-track approval plan for nicotine pouches has raised concerns for PM, as the initiative faces scrutiny over addiction risks among youth. This uncertainty complicates the company's efforts to expand its smoke-free product line, which has been a significant focus of its growth strategy. Despite the challenges, PM continues to emphasize its commitment to innovation and sustainability, as highlighted in its recent Value Report 2025.
The implications of this resistance could impact PM's market position and growth trajectory, especially as nicotine pouches represent a rapidly growing segment in the tobacco industry. Investors will be closely monitoring how the company navigates these regulatory hurdles while maintaining its leadership in smoke-free alternatives.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PM
Wall Street analysts forecast PM stock price to rise
11 Analyst Rating
8 Buy
3 Hold
0 Sell
Moderate Buy
Current: 157.330
Low
175.00
Averages
191.95
High
210.00
Current: 157.330
Low
175.00
Averages
191.95
High
210.00
About PM
Philip Morris International Inc. is an international tobacco company. The Company’s product portfolio primarily consists of cigarettes and smoke-free products. Its smoke-free business (SFB) also includes wellness and healthcare products, as well as consumer accessories, such as lighters and matches. The Company’s segments include Europe Region; South and Southeast Asia, Commonwealth of Independent States, Middle East and Africa Region (SSEA, CIS & MEA); East Asia, Australia & PMI Global Travel Retail (EA, AU & PMI GTR), and Americas Region. The Company's brands include Marlboro, HEETS, IQOS, IQOS ILUMA, TEREA, VEEV and ZYN. Its IQOS smoke-free product brand portfolio includes heated tobacco and nicotine-containing vapor products. Its international cigarette brands are Chesterfield, L&M, and Philip Morris. It also owns a number of local cigarette brands, such as Dji Sam Soe and Sampoerna A in Indonesia, and Fortune and Jackpot in the Philippines.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Altria Group's High-Yield Dividend and Cannabis Investment
- High-Yield Dividend: Altria Group offers a dividend yield exceeding 6%, providing investors with a steady cash flow, although its reliance on traditional cigarette sales remains high at 87%, indicating challenges in its transformation process.
- Cannabis Investment Status: Altria invested approximately $1.8 billion in Canadian cannabis company Cronos, holding about 41% of its shares, yet this investment is currently valued at only $429 million, reflecting market caution towards the cannabis industry.
- Revenue Trends: While Altria's annual revenue consistently exceeds $20 billion, its net revenue after excise taxes has declined annually since 2021, dropping from $21.1 billion to $20.1 billion, highlighting the long-term decline in the traditional cigarette market.
- Future Strategy: Altria launched its
See More
Altria: A High-Yield Investment in Tobacco Amid Cannabis Interest
- Strong Profitability: Altria Group generates over $20 billion in annual revenue, maintaining a high net margin of 75.86% despite the long-term decline in cigarette consumption, showcasing robust financial resilience in a competitive market.
- Dividend King Status: With a 56-year streak of increasing dividends and a current yield of 6.39%, Altria remains a favorite among investors, particularly those seeking high-yield opportunities, further solidifying its market position.
- Strategic Transformation: The company has launched its 'Moving Beyond Smoking' strategy, aiming to double revenue from next-generation tobacco products to $5 billion by 2028; despite regulatory challenges and competitive pressures, this transformation indicates a forward-looking approach to future markets.
- Investment in Cannabis Market: Altria invested approximately $1.8 billion in Canadian cannabis company Cronos in 2019, holding a 41% stake; although its current value is only $429 million, the potential for significant returns increases as marijuana legalization progresses.
See More
U.S. Consumer Spending Shows Unexpected Growth Amid Iran War
- Retail Sales Growth: U.S. retail sales rose 0.6% in February compared to the previous month, surpassing the expected 0.4% growth, indicating broad consumer spending increases in discretionary categories like department stores, restaurants, and cars, despite ongoing recession concerns.
- Impact of Energy Prices: The Iran war has led to a one-third increase in oil prices, raising fuel and shipping costs, prompting investors to seek safe investment avenues, with consumer staples stocks favored for their defensive and recession-resistant characteristics.
- Dollar General Performance: Dollar General has a strong track record during economic downturns, with management noting a shift in consumer behavior due to high energy prices and inflation, anticipating comparable sales and profit growth in 2025 as it continues to expand and renovate stores.
- Philip Morris Growth: Philip Morris International has pivoted successfully to next-gen products like Zyn and Iqos, achieving a 6.5% organic revenue growth to $40.6 billion, with a solid 3.7% dividend yield, positioning it well to weather market volatility amid the Iran conflict.
See More
Investors Heighten Concerns Over Economic Recession
- Recession Probability Fluctuations: According to Kalshi, the probability of a recession in 2025 exceeded 40% but dropped below 20% in February this year, only to rebound to 28% as of April 1, reflecting the impact of poor economic data and international tensions on market sentiment.
- GDP Revision Impact: The U.S. fourth-quarter GDP was revised down to 0.7% in March, increasing the risk of economic slowdown, and investors should be aware of the potential for two consecutive quarters of negative growth, which could be viewed as a shallow recession.
- Consumer Staples ETF Performance: The State Street Consumer Staples Select Sector SPDR ETF (XLP) has performed well amid market turmoil, rising 5% this year, with major holdings including Walmart (11.85%) and Coca-Cola (6.46%), demonstrating the resilience of consumer staples in uncertain economic conditions.
- Utilities ETF Stability: The Vanguard Utilities ETF (VPU) has also shown strong performance, up approximately 5% this year, with key holdings like NextEra Energy (11.95%) and Southern (6.38%), indicating that utility stocks' defensive characteristics are attracting investors amid recession fears.
See More
Analysis of High Dividend Stock Investment Strategy
- Philip Morris Growth: Despite declining global cigarette demand, Philip Morris International's smoke-free product volumes grew by 12.8% in 2025, demonstrating strong pricing power and unit economics in emerging markets, with expectations for significant increases in dividend per share in the future.
- Pfizer Dividend Advantage: Pfizer currently offers a dividend yield of 6.2%, and despite its stock price being down 55% from all-time highs, its investments in oncology and obesity drug markets may provide future growth potential, making it a stable income source.
- UnitedHealth Group Challenges: UnitedHealth Group has a dividend yield of 3.4%, and despite facing rising healthcare costs and cyberattack challenges, it is projected to rebound to $24 billion in operating earnings by 2026, supporting future dividend payments.
- Healthcare Spending Growth: As the U.S. population ages and healthcare costs inflate, healthcare spending is expected to continue rising, and while the insurance industry may not be popular, UnitedHealth Group's long-term growth potential remains noteworthy.
See More
Oil & Gas Refining and Marketing Stocks Decline
- Market Underperformance: On Wednesday, oil and gas refining and marketing stocks collectively fell by approximately 3.6%, indicating the pressure the sector is under amid increasing market volatility.
- Stock Drag: Gevo's share price dropped by about 10.8%, making it the worst performer in the industry, reflecting investor concerns regarding its future profitability.
- Aemetis Impact: Aemetis saw a decline of approximately 7.8% in its stock price, further exacerbating the overall downward trend in the sector, which may lead to decreased investor confidence in the company.
- Uncertain Industry Outlook: With overall market sentiment low, the future performance of the oil and gas refining and marketing sector faces uncertainty, potentially impacting the financing and expansion plans of related companies.
See More
Altria Group's High-Yield Dividend and Cannabis Investment
- High-Yield Dividend: Altria Group offers a dividend yield exceeding 6%, providing investors with a steady cash flow, although its reliance on traditional cigarette sales remains high at 87%, indicating challenges in its transformation process.
- Cannabis Investment Status: Altria invested approximately $1.8 billion in Canadian cannabis company Cronos, holding about 41% of its shares, yet this investment is currently valued at only $429 million, reflecting market caution towards the cannabis industry.
- Revenue Trends: While Altria's annual revenue consistently exceeds $20 billion, its net revenue after excise taxes has declined annually since 2021, dropping from $21.1 billion to $20.1 billion, highlighting the long-term decline in the traditional cigarette market.
- Future Strategy: Altria launched its
See More
Altria: A High-Yield Investment in Tobacco Amid Cannabis Interest
- Strong Profitability: Altria Group generates over $20 billion in annual revenue, maintaining a high net margin of 75.86% despite the long-term decline in cigarette consumption, showcasing robust financial resilience in a competitive market.
- Dividend King Status: With a 56-year streak of increasing dividends and a current yield of 6.39%, Altria remains a favorite among investors, particularly those seeking high-yield opportunities, further solidifying its market position.
- Strategic Transformation: The company has launched its 'Moving Beyond Smoking' strategy, aiming to double revenue from next-generation tobacco products to $5 billion by 2028; despite regulatory challenges and competitive pressures, this transformation indicates a forward-looking approach to future markets.
- Investment in Cannabis Market: Altria invested approximately $1.8 billion in Canadian cannabis company Cronos in 2019, holding a 41% stake; although its current value is only $429 million, the potential for significant returns increases as marijuana legalization progresses.
See More
U.S. Consumer Spending Shows Unexpected Growth Amid Iran War
- Retail Sales Growth: U.S. retail sales rose 0.6% in February compared to the previous month, surpassing the expected 0.4% growth, indicating broad consumer spending increases in discretionary categories like department stores, restaurants, and cars, despite ongoing recession concerns.
- Impact of Energy Prices: The Iran war has led to a one-third increase in oil prices, raising fuel and shipping costs, prompting investors to seek safe investment avenues, with consumer staples stocks favored for their defensive and recession-resistant characteristics.
- Dollar General Performance: Dollar General has a strong track record during economic downturns, with management noting a shift in consumer behavior due to high energy prices and inflation, anticipating comparable sales and profit growth in 2025 as it continues to expand and renovate stores.
- Philip Morris Growth: Philip Morris International has pivoted successfully to next-gen products like Zyn and Iqos, achieving a 6.5% organic revenue growth to $40.6 billion, with a solid 3.7% dividend yield, positioning it well to weather market volatility amid the Iran conflict.
See More
Investors Heighten Concerns Over Economic Recession
- Recession Probability Fluctuations: According to Kalshi, the probability of a recession in 2025 exceeded 40% but dropped below 20% in February this year, only to rebound to 28% as of April 1, reflecting the impact of poor economic data and international tensions on market sentiment.
- GDP Revision Impact: The U.S. fourth-quarter GDP was revised down to 0.7% in March, increasing the risk of economic slowdown, and investors should be aware of the potential for two consecutive quarters of negative growth, which could be viewed as a shallow recession.
- Consumer Staples ETF Performance: The State Street Consumer Staples Select Sector SPDR ETF (XLP) has performed well amid market turmoil, rising 5% this year, with major holdings including Walmart (11.85%) and Coca-Cola (6.46%), demonstrating the resilience of consumer staples in uncertain economic conditions.
- Utilities ETF Stability: The Vanguard Utilities ETF (VPU) has also shown strong performance, up approximately 5% this year, with key holdings like NextEra Energy (11.95%) and Southern (6.38%), indicating that utility stocks' defensive characteristics are attracting investors amid recession fears.
See More
Analysis of High Dividend Stock Investment Strategy
- Philip Morris Growth: Despite declining global cigarette demand, Philip Morris International's smoke-free product volumes grew by 12.8% in 2025, demonstrating strong pricing power and unit economics in emerging markets, with expectations for significant increases in dividend per share in the future.
- Pfizer Dividend Advantage: Pfizer currently offers a dividend yield of 6.2%, and despite its stock price being down 55% from all-time highs, its investments in oncology and obesity drug markets may provide future growth potential, making it a stable income source.
- UnitedHealth Group Challenges: UnitedHealth Group has a dividend yield of 3.4%, and despite facing rising healthcare costs and cyberattack challenges, it is projected to rebound to $24 billion in operating earnings by 2026, supporting future dividend payments.
- Healthcare Spending Growth: As the U.S. population ages and healthcare costs inflate, healthcare spending is expected to continue rising, and while the insurance industry may not be popular, UnitedHealth Group's long-term growth potential remains noteworthy.
See More
Oil & Gas Refining and Marketing Stocks Decline
- Market Underperformance: On Wednesday, oil and gas refining and marketing stocks collectively fell by approximately 3.6%, indicating the pressure the sector is under amid increasing market volatility.
- Stock Drag: Gevo's share price dropped by about 10.8%, making it the worst performer in the industry, reflecting investor concerns regarding its future profitability.
- Aemetis Impact: Aemetis saw a decline of approximately 7.8% in its stock price, further exacerbating the overall downward trend in the sector, which may lead to decreased investor confidence in the company.
- Uncertain Industry Outlook: With overall market sentiment low, the future performance of the oil and gas refining and marketing sector faces uncertainty, potentially impacting the financing and expansion plans of related companies.
See More
